---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008307"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:47:57.469212+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology doses first subject in Phase 1 trial of ADC PYX-201 for solid tumors

## Summary
- First subject dosed in open-label, dose-escalation Phase 1 trial PYX-201-101; preliminary data expected early 2024.
- PYX-201 targets EDB fibronectin, overexpressed in many solid tumors; minimal expression in normal adult tissues.
- Trial enrolling patients with NSCLC, HR+ breast, ovarian, thyroid, pancreatic, sarcoma, hepatocellular, kidney cancers.
- PYX-201 uses FACT platform licensed from Pfizer (2021) for site-specific conjugation and improved safety profile.
- Dosing milestone marks transition of Pyxis Oncology to a clinical-stage company.

## SEC filing metadata
- accession: 0000950170-23-008307
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023008307/0000950170-23-008307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023008307/pyxs-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008307
- JSON: https://secwatch.observer/filing/0000950170-23-008307.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.